Projet TransPot (Horizon 2020, appel à projets 2016)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

Mots clés : translational research, prostate cancer, model systems, systems biology, signalling, androgen, receptor, target for therapy

Participants :
- Mosaiques Diagnostics and Therapeutics (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Biomedical Research Foundation of the Academy of Athens (Grèce) — Partner, beneficiary, Recherche, subvention : 242386.92 €
- Erasmus MC (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255374.28 €
- University of Helsinki (Finlande) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- European Association of Urology (Suisse) — Partner, organization partner, Recherche, subvention : 0.0 €
- University of Glasgow (Royaume-Uni) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- Queen's University Belfast (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 204965.91 €
- University of Strathclyde (Royaume-Uni) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Newcastle University (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- Numares ag (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- University of Turku (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 269145.36 €
- Genomescan b.v. (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 319217.85 €
- Almac (United Kingdom) (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 273287.88 €
- Prostate Cancer UK (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Cancer Research UK (Royaume-Uni) — Partner, organization partner, Recherche, subvention : 0.0 €
- Tampere University (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 269145.36 €
- Carver wilde communications ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €